FOR IMMEDIATE RELEASE

NEW TRIAL OF EXTENDED-RELEASE MEDICATION FOR WINTER DEPRESSION BEGINS AT NEW YORK STATE PSYCHIATRIC INSTITUTE

New York, N.Y. (October 15, 2003) -- The short, dark days of winter are fast approaching, which for nearly a million New York area residents signals the reappearance of Seasonal Affective Disorder (SAD). People who suffer from SAD experience depression, fatigue, cravings for sweets and starches (with resulting weight gain), an increased need for sleep, and decreased social activity, according to Dr. Michael Terman of the Winter Depression Program at the New York State Psychiatric Institute, Columbia Presbyterian Medical Center. In the extreme, SAD sufferers find themselves deeply unproductive at work and sometimes become nearly incapacitated by the severity of their symptoms.

Earlier studies emphasized light therapy or medication initiated only after onset of the depression. The new study explores a contrasting option by beginning the clinical trial in the fall while participants are still feeling well. The FDA approved investigational drug, Wellbutrin XL, greatly extends the release of bupropion – the active agent – permitting full dosage with only 1 tablet per day. The investigators will closely follow patients’ mood and energy throughout the winter season. Participants who do not respond to the study tablets will be offered a trial of a new model light therapy box, alternate medication, or both.

In order to participate, patients must have experienced winter depressions for the past two years or longer. Candidates for the study can find clinic information at www.preventSAD.org, or can call (212) 543-5714. The study is sponsored by GlaxoSmithKline, Inc.

Interviews with Dr. Michael Terman are available upon request

The New York State Psychiatric Institute (PI) is America’s oldest psychiatric research institution. It is a leader in the advancement of knowledge about the understanding of mental illness and its treatment. It is noted for its work in depression and suicide, schizophrenia, anxiety and child psychiatric disorders. For more information about PI, check out our website at www.nyspi.cpmc.columbia.edu.

Go Back to News Releases